Optimization of sustained-release propranolol dosage form using factorial design and response surface methodology

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 10, 2004, Pages 1626-1629

  Huang, Yaw Bin ^a   Tsai, Yi Hung ^a   Yang, Wan Chiech ^a   Chang, Jui Sheng ^a   Pao Chu, W U ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dissolution test; Hydroxypropylmethylcellulose (HPMC); Propranolol; Response surface methodology

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; PROPRANOLOL; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELLULOSE; DRUG DERIVATIVE; METHYLCELLULOSE;

ARTICLE; DISSOLUTION; DRUG FORMULATION; DRUG PREFERENCE; DRUG SYNTHESIS; FACTORIAL ANALYSIS; MATHEMATICAL COMPUTING; MEASUREMENT; RESPONSE SURFACE METHOD; SUSTAINED DRUG RELEASE; TABLET; TIME; BIOLOGICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; MATHEMATICS; PH; REGRESSION ANALYSIS; SOLUBILITY;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HYDROGEN-ION CONCENTRATION; MATHEMATICS; METHYLCELLULOSE; MODELS, BIOLOGICAL; PROPRANOLOL; REGRESSION ANALYSIS; SOLUBILITY; TABLETS;

EID: 11844291470     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.1626     Document Type: Article

References (24)

1. Gao P., Meury R. H., J. Pharm. Sci., 85, 725-731 (1996).
2. Gohel M. C., Amin A. F., J. Control Release, 51, 115-122 (1998).
3. Ford J. L., Rubinstein M. H., Hogan J. E., Int. J. Pharm., 24, 327-338 (1985).
4. Ford J. L., Mitchell K., Rowe P., Armstrong D. J., Elliott P. N. C., Rostron, C., Hogan J. E., Int. J. Pharm., 71, 95-104 (1991).
5. Sako K., Sawada T., Nakashima H., Yokohama S., Sonobe T., J. Control Release, 81, 165-172 (2002).
6. Rekhi S. G., Porter S. C., Jambhekar S. S., Drug Dev. Ind. Pharm., 221, 709-729 (1995).
7. Taylan B., Capan Y., Guven O., Kes S., Hincal A., J. Control Release, 38, 11-20 (1996).
8. Eddington N. D., Ashraf M., Augsburger L. L., Leslie J. L., Fossler M. J., Lesko L. J., Shah V. P., Rekhi G. S., Pharm. Dev. Tech., 3, 535-547 (1998).
9. Sonaglio D., Bataille B., Ortigosa C., Jacob M., Khan M., Int. J. Pharm., 115, 53-60 (1995).
10. Bouckaert S., Massart D. L., Massart B., Rremon J. P., Drug Dev. Ind. Pharm., 22, 321-327 (1996).
11. Karnachi A. A., Khan M. A., Int. J. Pharm., 131, 9-17 (1996).
12. Wu P. C., Obata Y., Fujikawa M., Li C. J., Higashiyama K., Takayama K., J. Pharm. Sci., 90, 1004-1014 (2001).
13. USP XXIII, United States Pharmacopeial Convention, Inc., Rockville, MD, 1995, p. 1328.
14. Takayama K., Fujikawa M., Nagai T., Pharm. Res., 16, 1-6 (1999).
15. United States Food and Drug Administration (FDA), Guidance for industry, dissolution testing of immediate release solid oral dosage forms, August 1997.
16. Ritger P. L., Peppas N. S., J. Control Release, 5, 37-42 (1987).
17. Huang Y. B., Tsai Y. H., Yang W. C., Chang J. S., Wu P. C., J. Appl. Polym. Sci., 93, 1886-1890 (2004).
18. Cressman W. A., Summer D., J. Pharm. Sci., 60, 132-134 (1971).
19. Uchida T., Kawata M., Goto S., J. Pharmacobio-Dyn., 9, 631-637 (1986).
20. Katori N., Okudaria K., Aoyagi N., Takeda Y., Uchiyama M., J. Pharmacobio-Dyn., 14, 567-575 (1991).
21. Feely L. C., Davis S. S., Int. J. Pharm., 41, 83-90 (1988).
22. Efentakis M., Al-Hmound H., Choulis N. N., Acta Pharm. Technol., 36, 237-239 (1990).
23. Vlachou M., Hani N., Efentakis M., Tarantili P. A., Andreopoulos A. G., J. Biomater. Appl., 15, 65-77 (2000).
24. Nokhodchi A., Norouzi-Sani S., Siahi-Shadbad M. R., Lotfipoor F., Saeedi M., Eur. J. Pharm. Sci., 54, 349-356 (2002).